Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Orchard Therapeutics Plc ADR (NQ: ORTX )

5.300 -0.070 (-1.30%)
Streaming Delayed Price Updated: 2:07 PM EDT, Mar 22, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 49,848
Open 5.310
Bid (Size) 5.240 (4)
Ask (Size) 5.330 (2)
Prev. Close 5.370
Today's Range 5.150 - 5.350
52wk Range 3.601 - 8.875
Shares Outstanding 183,984,499
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Orchard Therapeutics Completes ADS Ratio Change
From Orchard Therapeutics (Europe) Limited
Via Globe NewsWire
Why Aclaris Therapeutics Shares Are Trading Lower By Around 55%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Unicycive Therapeutics, Inc. (NASDAQ: UNCY) shares surged 159% to $1.27 after the company announced a private placement of up to $130 million in gross proceeds to commercialize and launch... 
Via Benzinga

Performance

YTD
+20.45%
+20.45%
1 Month
-3.64%
-3.64%
3 Month
+35.90%
+35.90%
6 Month
+17.08%
+17.08%
1 Year
-34.48%
-34.48%

More News

Read More
Orchard Therapeutics Provides Business Update and Reports 2022 Financial Results
From Orchard Therapeutics (Europe) Limited
Via Globe NewsWire
Orchard Therapeutics Announces Strategic Financing Totalling up to $188 Million
From Orchard Therapeutics (Europe) Limited
Via Globe NewsWire
Orchard Therapeutics to Present at Multiple Investor Conferences in March 2023
From Orchard Therapeutics (Europe) Limited
Via Globe NewsWire
Orchard Therapeutics Announces Agreement Enabling Reimbursed Access to Libmeldy for All Eligible MLD Patients in Sweden
From Orchard Therapeutics (Europe) Limited
Via Globe NewsWire
Orchard Therapeutics Announces Presentation of Updated Integrated Analysis of OTL-200 in MLD and Reports Progress with Newborn Screening Efforts at the 19th Annual WORLDSymposium™
From Orchard Therapeutics (Europe) Limited
Via Globe NewsWire
Orchard Therapeutics Announces Proposed ADS Ratio Change
From Orchard Therapeutics (Europe) Limited
Via Globe NewsWire
Orchard Therapeutics Announces Comprehensive Presence at 19th Annual WORLDSymposium
From Orchard Therapeutics (Europe) Limited
Via Globe NewsWire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Via InvestorPlace
Orchard Therapeutics Highlights Recent Progress Across HSC Gene Therapy Portfolio and Outlines Key 2023 Milestones
From Orchard Therapeutics (Europe) Limited
Via Globe NewsWire
Why Graphite Bio Shares Are Trading Lower By 50%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Why Spruce Biosciences Shares Are Trading Higher By 100%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Why ABVC BioPharma Shares Are Trading Higher By 129%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Orchard Therapeutics Announces U.S. FDA Clearance of IND Application for OTL-203 in MPS-IH
From Orchard Therapeutics (Europe) Limited
Via Globe NewsWire
Orchard Therapeutics Announces Promising Early Neurocognitive Outcomes from Ongoing Proof-of-concept Study of OTL-201 in MPS-IIIA
From Orchard Therapeutics (Europe) Limited
Via Globe NewsWire
Orchard Therapeutics Announces Swissmedic Validation of the Marketing Authorization Application for Libmeldy (atidarsagene autotemcel)
From Orchard Therapeutics (Europe) Limited
Via Globe NewsWire
Orchard Therapeutics Reports Third Quarter 2022 Financial Results and Reviews Recent Business Highlights
From Orchard Therapeutics (Europe) Limited
Via Globe NewsWire
Earnings Scheduled For November 14, 2022
Via Benzinga
Orchard Therapeutics to Present at Multiple Investor Conferences in November 2022
From Orchard Therapeutics (Europe) Limited
Via Globe NewsWire
Orchard Therapeutics to Webcast Conference Call of Third Quarter 2022 Financial Results
From Orchard Therapeutics (Europe) Limited
Via Globe NewsWire
Orchard Therapeutics Announces First Neurocognitive Data from OTL-201 Study in MPS-IIIA Accepted for Oral Presentation at ASH 2022
From Orchard Therapeutics (Europe) Limited
Via Globe NewsWire
Why Olaplex Holdings Shares Are Trading Lower By 42%; Here Are 27 Stocks Moving Premarket
Via Benzinga
Orchard Announces Multiple Presentations at 2022 ESGCT Annual Congress Showing the Potential of HSC Gene Therapy in Several Therapeutic Areas
From Orchard Therapeutics (Europe) Limited
Via Globe NewsWire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.